Scalper1 News
Specialty drugmakers and IBD 50 stocks Actavis (ACT) and Akorn were headed in opposite directions in the stock market today after the companies reported their second-quarter earnings and updated their guidance. Actavis’ earnings rose 70% over the year-earlier quarter to $3.42 a share, beating analysts’ consensus by 5 cents. Sales rose 34% to $2.67 billion, more than $100 million above estimates. That, however, was the old Actavis. What really Scalper1 News
Scalper1 News